Join Dr. Alan Bonder, Associate Professor of Medicine at Harvard Medical School and Medical Director of Liver Transplantation, for an expert overview on the latest AASLD guideline updates for Primary Biliary Cholangitis (PBC). This in-depth session highlights key diagnostic criteria—such as AMA positivity, elevated alkaline phosphatase, and histologic confirmation—and walks through evidence-based treatment pathways for managing PBC. Dr. Bonder discusses the pivotal role of ursodeoxycholic acid (UDCA) as first-line therapy and emphasizes the importance of risk stratification using tools like FibroScan and biochemical markers to identify non-responders.

He outlines thresholds for therapeutic response and reviews the FDA-approved second-line therapies, including obeticholic acid and the three new agents approved in summer 2024, while addressing safety concerns and boxed warnings. Dr. Bonder also underscores the need to address quality of life, managing symptoms like fatigue, pruritus, and abdominal pain—often overlooked but impactful for patients with PBC. With clinical pearls on when to escalate care or refer for liver transplantation, this session offers a comprehensive, practical roadmap for optimizing PBC outcomes today and in the future.